Jan 2016
Jan 2016 EdiGene Corporation founded
Apr 2016
Established fully owned US subsidiary, EdiGENE Inc. (Now Modalis Therapeutics Inc.)
Apr 2017
Initial research collaboration formed with Astellas Pharma Inc.
Sep 2017
Obtained license on engineered Cas9 technology from University of Tokyo
Dec 2017
Entered into research collaboration with Fujifilm
Feb 2019
Established a license agreement on a genetic disorder with Astellas Pharma Inc.
Mar 2019
US subsidiary relocated to the new facility
Aug 2019
EdiGene renamed to Modalis Therapeutics
Sep 2019
Established 2nd license agreement for additional genetic disorder with Astellas Pharma Inc.
Nov 2019
Collaboration agreement with Eisai Co., Ltd.
Aug 2020
Listing on Mothers, Tokyo Stock Exchange (Ticker symbol: 4883)